|
The Indian pharmaceutical industry is working to take advantage of Generative AI potential to transform drug discovery. Functions such as establishing connections between the causative pathways and showing the genetic predispositions have the potential to enable successful interventions and revert disease progression.
There is no better time for pharmaceutical companies to seize the transformative potential of generative AI and what’s more is that they wouldn’t have to take this step without digital innovation support. GenAI has become a part of almost all aspects of the pharmaceutical industry, enhancing the rate of drug discovery, clinical trials, pattern recognition, and above all, reducing the costs involved, said Kapil Mehta, senior director, technology solutions, Visionet.
Integrating technological progressions successfully, calls for an integrated digital innovation system–something that can enable experts in the pharmaceutical industry to optimize their work while facilitating faster drug testing and time to market. Although the disruptive effect of AI on drug discovery is undisputed, pharmaceutical businesses need to also be mindful about data quality assurance and the transparency of the AI model.
Engaging in strategic collaborations with businesses that specialize in AI, machine learning and other technologies, can bridge the gaps in the healthcare system, protecting company and customer data while improving overall customer satisfaction. Generative AI is transforming healthcare and pharmaceutical sectors, promising a more efficient and effective system. Owing to its potential, the global AI healthcare market is expected to grow at a compound annual growth rate of 37.5% until 2030, Mehta told Pharmabiz in an email.
For instance, generative AI rapidly identifies potential drug candidates by analyzing vast datasets of chemical compounds and biological data. It predicts the success of compounds in clinical trials, reducing time and resources spent on unsuccessful candidates. The technology also develops personalized treatments by analyzing genetic, environmental, and lifestyle data, ensuring patients receive the most effective therapies with minimal side effects, he stated.
In addition, generative AI models complex biological systems accurately, providing insights into disease mechanisms and potential therapeutic targets. This understanding enables the design of more effective drugs. Through fostering collaboration between researchers, clinicians, and pharmaceutical companies, genAI is accelerating the discovery of new treatments and translating scientific advancements into clinical practice.
Moreover, by streamlining the expensive and time-consuming drug discovery process by automating labor-intensive tasks, GenAI generates and tests potential compounds quickly, identifying promising candidates for further development. It has been estimated that the technology could generate $60 billion to $110 billion a year in economic value for the pharma and medical-product industries globally.
The future of AI in drug discovery is multifaceted. AI can enhance R&D in the pharma sector, enabling innovations and discoveries to come to fruition at a faster rate year-on-year. With the right tech investments and collaborations, the pharmaceutical industry can engage in finding cures for untreatable diseases. A comprehensive approach to any emerging technology and its mindful implementation could lead India further up the global healthcare value chain, Mehta said, adding that Visionet works with both Indian and global pharmaceutical companies helping them leverage advanced AI algorithms to streamline drug discovery process, for reducing costs, and accelerate time-to-market for new inventions.
|